Group items tagged

The Agency for Toxic Substances and Disease Registry (ATSDR) is soliciting investigator-initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. The National ALS Registry's goals are to estimate the number of new ALS cases each year, estimate the number of people who have ALS at a specific point in time, better understand who gets ALS, and identify what contributing factors, including environmental, may affect ALS.

The ALS Therapy Alliance was established in 2000 to facilitate ALS research projects and collaborations among a diverse group of scientists and clinicians at multiple institutions working to cure amyotrophic lateral sclerosis. The alliance represents a unique collaborative enterprise that spans multiple laboratories, universities, and disciplines.   Today, the ATA partners with corporations, biotech and pharmaceutical firms, manufacturers, and the media to create awareness and raise funds for ALS research through its annual Breakthrough ALS campaign. To date, more than $30 million has been raised to fund research for finding a cure for this devastating disease.   The ALS Therapy Alliance is accepting applications from investigators for ALS research projects. Grants ranging from $100,000 to $1 million over one to three years will be awarded to projects -- including but not limited to basic, clinical, and translational research and clinical trials - aimed at developing a better understanding of, or treatments for, ALS.   National and international nonprofit organizations and for-profit companies are eligible to apply.

The Therapeutic Development Award supports research ranging from validation of therapeutic leads to U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited ALS experience are strongly encouraged to collaborate with those having substantial expertise in ALS research and/or ALS model systems. Examples of activities that will be supported by this award include: * Confirmation of candidate therapeutics obtained from screening or by other means, including optimization of potency and pharmacological properties and testing of derivatives and sister compounds * Validation of early pilot studies, including the use of multiple ALS model systems and/or replicating preliminary data with more time points or additional doses * Studies on formulation and stability leading to Good Manufacturing Practice (GMP) production methods * IND-enabling studies, to include compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies in relevant model systems Validation of treatment approaches in appropriately powered and controlled studies using biological correlates of disease activity and progression in pre-existing, de-identified human specimens from well-characterized patient cohorts is encouraged. Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries (e.g., Centers for Disease Control and Prevention National ALS Registry and/or Biorepository; https://wwwn.cdc.gov/als/).

The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism.New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community.Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities.Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and highDoD FY15 ALSRP Therapeutic Idea Award 4potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide.

The Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)- enabling studies. The proposed studies are expected to be empirical in nature and product- driven. Applicants with limited ALS experience are strongly encouraged to collaborate with those having substantial expertise in ALS research and/or ALS model systems. Examples of activities that will be supported by this award include: Confirmation of candidate therapeutics obtained from screening or by other means, including optimization of potency and pharmacological properties and testing of derivatives and sister compounds Validation of early pilot studies, including the use of multiple ALS model systems and/or replicating preliminary data with more time points or additional doses Studies on formulation and stability leading to Good Manufacturing Practice (GMP) production methods IND-enabling studies, to include compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies in relevant model system

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of high- throughput screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

The purpose of this funding opportunity announcement (FOA) is to allow for investigator-initiated research that will further the understanding of potential risk factors for amyotrophic lateral sclerosis (ALS), while supporting the goals of the National ALS Registry.

The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission.

MDA supports research aimed at developing treatments for the muscular dystrophies and related diseases of the neuromuscular system. These are the muscular dystrophies (among which are Duchenne and Becker); motor neuron diseases (including ALS and SMA); the peripheral nerve disorders (CMT and Friedreich's ataxia); inflammatory myopathies; disorders of the neuromuscular junction; metabolic diseases of muscle as well as other myopathies.

Much of the research MDA supports is what is termed "basic" research: research investigating the fundamental biological processes of nerves, muscles and what goes awry to cause disease. Much of this research is not aimed at one specific disease but can apply to many neuromuscular diseases. Projects at this stage, for example, may initially seek answers about a muscular dystrophy, but ultimately lead to a therapy for ALS. This is how MDA's broad coverage of diseases can be so powerful. Basic research that results in the identification of a therapeutic target also may be called "discovery research."

The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS), and other neuromuscular diseases. It advances this mission by funding research; providing comprehensive healthcare services and support to MDA families nationwide; and rallying communities to fight back through advocacy, fundraising, and local engagement.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The anticipated direct costs budgeted for the entire period of performance for an FY18 OCRP Investigator-Initiated Research Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191.

AFTD Basic Science Pilot Grants provide seed funding for innovative research projects that expand our understanding of the biology or pathophysiology of frontotemporal degeneration (FTD). The FTD disorders include: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS/MND. Applications are welcome from investigators at not-for-profit institutions or biotechnology startup organizations. Pilot Grant funded projects are intended to generate data that will support follow-on grant applications to the National Institutes of Health (NIH) or other public or private agencies.

Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.